Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Etubics Corporation
Seattle, Washington, United Statesetubics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The Etubics Platform demonstrated the ability to overcome challenges seen with earlier viral vectors in Phase I and II trials. It enabled rapid development of immunotherapies and vaccines for cancer and infectious diseases. Clinical results showed promise but detailed efficacy data are not publicly available.
- Therapeutic areas
- OncologyRare DiseasesInfectious Diseases
- Modalities
- Gene delivery platform (adenovirus vector)Immunotherapies (immunotherapeutic drugs)Preventive vaccines
- Industry
- Biotech
02
Partnerships
National Cancer Institute – collaboration on novel immunotherapeutic cancer treatments in clinical trials.
Beyond the preview
Go deeper on Etubics Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Etubics Corporation.